Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from GENinCode UK Ltd. ( (GB:GENI) ) is now available.
GENinCode Plc has launched a retail share offer via the Winterflood Retail Access Platform to raise up to £500,000 through the issue of up to 50 million new ordinary shares at 1 pence per share, matching the price of a concurrent placing and subscription intended to raise at least £3.5 million. The WRAP Retail Offer, which is open to eligible UK retail investors through participating intermediaries and subject to shareholder approval and admission of the new shares to trading on AIM in February 2026, is designed to give private investors the opportunity to participate alongside institutional backers, potentially broadening the shareholder base and supporting the company’s financing needs on the same discounted terms as the institutional raise.
The most recent analyst rating on (GB:GENI) stock is a Sell with a £2.00 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.
Spark’s Take on GB:GENI Stock
According to Spark, TipRanks’ AI Analyst, GB:GENI is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, negative operating cash flow, and declining equity). Technicals add pressure as the stock trades below major moving averages with negative MACD, while valuation is constrained by negative earnings and no dividend yield data.
To see Spark’s full report on GB:GENI stock, click here.
More about GENinCode UK Ltd.
GENinCode Plc is an AIM-quoted genetics company focused on the prevention of cardiovascular disease and the early detection of ovarian cancer. The company develops and commercialises genomic tests and diagnostics aimed at improving risk prediction and early intervention in these disease areas, targeting both healthcare providers and patients in markets where personalised medicine and preventative care are gaining traction.
Average Trading Volume: 816,018
Technical Sentiment Signal: Strong Sell
Current Market Cap: £5.45M
Learn more about GENI stock on TipRanks’ Stock Analysis page.